The European Medicines Agency has moved toward withdrawing marketing authorization for Amgen and Vifor’s inflammatory drug Tavneos, concluding that benefits no longer outweigh risks. The CHMP recommendation follows an EU review, while an FDA proposal to withdraw the drug in the US is also expected to proceed to a hearing. Separately, coverage indicates that both regulators are challenging the approval basis, pointing to data integrity concerns. In Europe, the CHMP’s action signals a likely revocation pathway, while the US process suggests Tavneos may face additional scrutiny at an FDA proceeding. For the broader biotech space, the case underscores how post-authorization evidence and manufacturing/data standards can rapidly shift a product’s risk-benefit profile, affecting contract structures and downstream commercial planning for stakeholders supporting the drug’s supply chain and indication strategy.